IP Explained: Three forms of IP protections for medicines

Intellectual property (IP) protections for the biopharmaceutical sector provide incentives that help to promote the discovery and development of life-saving medicines for patients and foster a...
Read More
Three reasons the Senate Finance package is the wrong approach for patients

For more than a decade, Medicare Part D has successfully provided seniors and people with disabilities comprehensive prescription drug coverage, while its unique market-based structure has kept...
Read More
Fact Check: How hospitals continue to drive health care spending

There is a lot of talk about health care costs in the United States that is mostly centered on prescription medicine spending, overlooking the largest share of U.S. health care spending – hospital...
Read More
340B Spotlight: How for-profit middlemen are taking advantage of a program meant to support nonprofit entities and patients

Congress created the 340B program to help safety-net providers, like federally-funded safety net clinics, access discounts on prescription medicines for vulnerable or uninsured patients....
Read More
New analysis: Government intervention in Part B threatens patient access to medicines

A new analysis from Avalere looked at how access to medicines in Part B may be impacted if the government only covered a certain list of medicines, an approach known as applying a national formulary....
Read More
Three things to know about the Part D GAO report

The Government Accountability Office (GAO) recently released a new report looking at Medicare Part D and the role of Pharmacy Benefit Managers (PBMs) in the program. While the report provides a...
Read More
Four Things You Should Know About AARP

As lawmakers in Washington consider policies to make changes to Medicare prescription drug coverage, one solution that would provide immediate relief is sharing the savings biopharmaceutical...
Read More
What they’re saying: Safety is top concern for recent drug importation proposal

Last week, the U.S. Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA) released their “Safe Importation Action Plan,” which would allow importation of...
Read More
IP Explained: How patents support innovation throughout the biopharmaceutical lifecycle

Patents are unique in that they are a form of IP protection established in the U.S. Constitution that grants inventors the right to their inventions without others being able to make, use or sell...
Read More
ICYMI: Canadian government, stakeholders voice concerns with drug importation proposals

This week, the U.S. Department of Health and Human Services and the U.S. Food and Drug Administration announced their “Safe Importation Action Plan.” While patients are rightfully concerned about the...
Read More